Loading organizations...
Based in Seoul, South Korea, Eutilex is a biotechnology company that develops immunotherapy solutions like EU101 antibody treatments and CAR T cell therapies to activate T cells against complex cancers. The immune oncology enterprise was founded in 2015 by former CEO Byoung Kwon and supplies specialized clinical treatments to hospitals across Asia, Europe, and North America. The publicly listed KOSDAQ firm reached a peak market capitalization of 991 billion won in 2019 and later secured 22 billion won during a May 2021 private investment round. Eutilex has received financial backing from several notable institutional investors, including Focus Asset Management, Susung Asset Management, DS Asset Management, and Kolon Investment. In December 2025, the organization underwent a significant ownership transition when a controlling stake of over four million shares was sold to Cheongan Investment for ten billion won.
Eutilex has raised $18.1M across 1 funding round.
Eutilex has raised $18.1M in total across 1 funding round.
Eutilex has raised $18.1M in total across 1 funding round.
Eutilex's investors include DS Asset Management, G.N. Tech Venture Capital, Kolon Investment, SNU Bio Angel.
Eutilex has raised $18.1M across 1 funding round. Most recently, it raised $18.1M Series A in December 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 8, 2016 | $18.1M Series A | — | DS Asset Management, G.n. Tech Venture Capital, Kolon Investment, SNU BIO Angel | Announced |
